APIS Assay Technologies ^Company

APIS Assay Technologies is committed to realizing the clinical potential of systems biology and medicine in diagnostics and personalization treatment. It seeks to develop biomarkers that deliver significant improvements in the prediction and prevention of disease. The APIS Assay Technologies' programme uses Artificial Intelligence enabled data mining, identifies novel biomarkers with industrial potential. Their Current Areas of Interest: cancer, including breast cancer, leukaemia (including AML), liver cancer and fibrosis, long noncoding RNAs in cancer and other diseases, Asthma, ARDS, infectious disease detection, including SARS-CoV-19, antibiotic resistance markers, sepsis.